COLLEGE BUSINESS & TECHNOLOGY PARK, DUBLIN 15, L2
Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis
Keenova Therapeutics to Sell Percocet and Endocet Businesses for $250 Million
Shareholder Vote Results from 2026 Annual General Meeting
Reports First Quarter 2026 Financial Results, Reports Unaudited Non-GAAP Pro Forma Combined Net Sales and Adjusted EBITDA
Annual Report to Security Holders
Earnings Release
CEO Sigurdur Olafsson Signs New Employment Agreement Until 2028
News, Material Contracts
Q1
FY 2025
Notice of Late Filing for Annual Report
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus Filed Pursuant to Rule 425
Prospectus filed pursuant to Rule 424(b)(3)
S-4/A
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Specialized Disclosure Report
S-8 POS
Correspondence